In stratified analyses, we found that NUE1 increased predicted worse OS in T1 stage and pathologic stage 1 subgroups, and the expression of NEU1 showed no statistical significance for the OS of pathologic stage 2/3 or T2/3 HCC patients. This evidence concerns the gene NEU1 and hepatocellular carcinoma.